Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally. It collects and processes regulated and specialized waste for disposal services; and collects personal and confidential information for secure destruction, as well as offers training, consulting, recall/return, communication, and compliance services. The company's services also include medical waste disposal, pharmaceutical waste disposal, hazardous waste management, sustainability solutions for expired or unused inventory, secure information destruction of documents and e-media, and compliance services; and regulated recall and returns management communication, logistics, and data management services for expired, withdrawn, or recalled products. In addition, it offers compliance programs under the Steri-Safe, Clinical Services, First Practice Management, SeguriMed, and EnviroAssure brand names; and live voice and automated communication services, including afterhours answering, appointment scheduling, appointment reminders, secure messaging, and event registration. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, long-term care facilities, etc.; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was founded in 1989 and is based in Lake Forest, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Sanitary services
Sub-IndustryEnvironmental & Facilities Services
SectorBusiness Services
Current SymbolNASDAQ:SRCL
Previous Symbol
CUSIP85891210
Phone847-367-5910
Debt
Debt-to-Equity Ratio0.93
Current Ratio1.07
Quick Ratio1.07
Price-To-Earnings
Trailing P/E Ratio10.61
Forward P/E Ratio10.54
P/E Growth1.18
Sales & Book Value
Annual Sales$3.58 billion
Price / Sales1.16
Cash Flow$7.6225 per share
Price / Cash6.04
Book Value$32.37 per share
Price / Book1.42
Profitability
EPS (Most Recent Fiscal Year)$4.34
Net Income$42.40 million
Net Margins4.63%
Return on Equity13.74%
Return on Assets5.77%
Miscellaneous
Employees645
Outstanding Shares90,600,000
Market Cap$4.12 billion
OptionableOptionable
Stericycle (NASDAQ:SRCL) Frequently Asked Questions
What is Stericycle's stock symbol?
Stericycle trades on the NASDAQ under the ticker symbol "SRCL."
How were Stericycle's earnings last quarter?
Stericycle Inc (NASDAQ:SRCL) released its quarterly earnings results on Thursday, November, 1st. The business services provider reported $1.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.01 by $0.02. The business services provider earned $854.90 million during the quarter, compared to analyst estimates of $856.36 million. Stericycle had a return on equity of 13.74% and a net margin of 4.63%. Stericycle's revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.10 earnings per share. View Stericycle's Earnings History.
When is Stericycle's next earnings date?
What guidance has Stericycle issued on next quarter's earnings?
Stericycle updated its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of $4.31-4.41 for the period, compared to the Thomson Reuters consensus estimate of $4.44. The company issued revenue guidance of $3.44-3.52 billion, compared to the consensus revenue estimate of $3.50 billion.Stericycle also updated its FY 2018 guidance to $4.31-4.41 EPS.
What price target have analysts set for SRCL?
9 equities research analysts have issued twelve-month price objectives for Stericycle's shares. Their forecasts range from $50.00 to $85.00. On average, they anticipate Stericycle's stock price to reach $63.1429 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Stericycle.
What is the consensus analysts' recommendation for Stericycle?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stericycle in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Stericycle.
What are Wall Street analysts saying about Stericycle stock?
Here are some recent quotes from research analysts about Stericycle stock:
- 1. Robert W. Baird analysts commented, "Driven by the successful turnaround efforts at Terminix and solid performance in FSG, adjusted EBITDA of $105M was in line with our estimate and beat the Street’s $101M estimate; revenues of $496M also beat our/Street’s $489M/$486M estimates. Management raised FY2018 revenue guidance to $1,885-1,900M ($1,875M-$1,890M previously), owing to the transformation efforts and performance of acquisitions at Terminix. The company reiterated adjusted EBITDA guidance of $425-435M, as it continues to invest in the business to create sustainable, long-term growth. Maintain Outperform." (11/6/2018)
- 2. According to Zacks Investment Research, "Shares of Stericycle have underperformed the industry it belongs to in the past year. The company continues to operate in a highly-competitive industry where the barriers to entry are very low in the regulated waste collection and disposal business. Vast international presence exposes Stericycle to foreign currency exchange-rate risks. A debt-laden balance sheet remains a major concern. Despite such headwinds, Stericycle continues to increase its market share and expand geographic base with the help of acquisitions in both domestic and international markets. We also appreciate the company's consistent efforts to develop internally. To better meet customer demands, the company has been improving its solution offerings and platforms. Stericycle's focus on providing regulated business-to-business services to smaller businesses should boost its offerings." (10/9/2018)
Has Stericycle been receiving favorable news coverage?
News coverage about SRCL stock has trended very positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stericycle earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news stories about the business services provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Stericycle's key competitors?
Who are Stericycle's key executives?
Stericycle's management team includes the folowing people:
- Mr. Charles A. Alutto, CEO & Director (Age 52)
- Mr. Daniel V. Ginnetti, Exec. VP & CFO (Age 49)
- Ms. Ruth-Ellen Abdulmassih, Exec. VP of Communication & Related Services (Age 56)
- Ms. Brenda R. Frank, Exec. VP & Chief People Officer (Age 48)
- Ms. Cindy J. Miller, Pres & COO
Who are Stericycle's major shareholders?
Stericycle's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.97%), Baillie Gifford & Co. (5.95%), Wells Fargo & Company MN (3.93%), Clarkston Capital Partners LLC (2.94%), FMR LLC (2.65%) and Fairpointe Capital LLC (1.97%). Company insiders that own Stericycle stock include Brian P Anderson, Charles A Alutto, Daniel Ginnetti, Jack W Schuler, John Patience, Mark C Miller, Mike S Zafirovski, Robert S Murley and Thomas D Brown. View Institutional Ownership Trends for Stericycle.
Which major investors are selling Stericycle stock?
SRCL stock was sold by a variety of institutional investors in the last quarter, including Fairpointe Capital LLC, Jennison Associates LLC, Los Angeles Capital Management & Equity Research Inc., Tobam, Mondrian Investment Partners LTD, Thompson Siegel & Walmsley LLC, SG Americas Securities LLC and Korea Investment CORP. Company insiders that have sold Stericycle company stock in the last year include Brian P Anderson, Charles A Alutto, Daniel Ginnetti, John Patience, Mark C Miller and Thomas D Brown. View Insider Buying and Selling for Stericycle.
Which major investors are buying Stericycle stock?
SRCL stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., FMR LLC, Allianz Asset Management GmbH, Veritas Asset Management LLP, Neuberger Berman Group LLC, Earnest Partners LLC, Man Group plc and Standard Life Aberdeen plc. Company insiders that have bought Stericycle stock in the last two years include Brian P Anderson, Jack W Schuler, Mike S Zafirovski and Robert S Murley. View Insider Buying and Selling for Stericycle.
How do I buy shares of Stericycle?
Shares of SRCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stericycle's stock price today?
One share of SRCL stock can currently be purchased for approximately $46.04.
How big of a company is Stericycle?
Stericycle has a market capitalization of $4.12 billion and generates $3.58 billion in revenue each year. The business services provider earns $42.40 million in net income (profit) each year or $4.34 on an earnings per share basis. Stericycle employs 645 workers across the globe.
What is Stericycle's official website?
How can I contact Stericycle?
Stericycle's mailing address is 28161 NORTH KEITH DRIVE, LAKE FOREST IL, 60045. The business services provider can be reached via phone at 847-367-5910 or via email at [email protected]
MarketBeat Community Rating for Stericycle (NASDAQ SRCL)
MarketBeat's community ratings are surveys of what our community members think about Stericycle and other stocks. Vote "Outperform" if you believe SRCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
